Drug General Information |
Drug ID |
D09LPL
|
Former ID |
DNC004132
|
Drug Name |
SU-11652
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C22H27ClN4O2
|
InChI |
InChI=1S/C22H27ClN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-
|
InChIKey |
XPLJEFSRINKZLC-ATVHPVEESA-N
|
PubChem Compound ID |
|
PubChem Substance ID |
8034463, 10318719, 10318955, 11061330, 14981640, 26759573, 39301728, 47499818, 57361295, 74593832, 99302781, 99444480, 103175627, 113911641, 134341337, 137184666, 140170705, 160969064, 163687282, 175607440, 177748402, 178102665, 179230473, 204359716, 228252546
|
Target and Pathway |
Target(s) |
Beta platelet-derived growth factor receptor |
Target Info |
Inhibitor |
[2]
|
Alpha platelet-derived growth factor receptor |
Target Info |
Inhibitor |
[2]
|
Vascular endothelial growth factor receptor 1 |
Target Info |
Inhibitor |
[2]
|
Vascular endothelial growth factor receptor 2 |
Target Info |
Inhibitor |
[2]
|
KEGG Pathway
|
MAPK signaling pathway
|
Ras signaling pathway
|
Rap1 signaling pathway
|
Calcium signaling pathway
|
Cytokine-cytokine receptor interaction
|
PI3K-Akt signaling pathway
|
Focal adhesion
|
Gap junction
|
Regulation of actin cytoskeleton
|
HTLV-I infection
|
Pathways in cancer
|
MicroRNAs in cancer
|
Glioma
|
Prostate cancer
|
Melanoma
|
Central carbon metabolism in cancer
|
Choline metabolism in cancerhsa04010:MAPK signaling pathway
|
Endocytosis
|
Choline metabolism in cancerhsa04014:Ras signaling pathway
|
HIF-1 signaling pathway
|
Transcriptional misregulation in cancer
|
Rheumatoid arthritishsa04014:Ras signaling pathway
|
VEGF signaling pathway
|
Proteoglycans in cancer
|
NetPath Pathway
|
TGF_beta_Receptor Signaling PathwayNetPath_14:IL2 Signaling Pathway
|
PANTHER Pathway
|
Angiogenesis
|
PDGF signaling pathwayP00005:Angiogenesis
|
VEGF signaling pathway
|
Pathway Interaction Database
|
Signaling events mediated by PTP1B
|
Beta3 integrin cell surface interactions
|
S1P3 pathway
|
Nectin adhesion pathway
|
Signaling events mediated by TCPTP
|
SHP2 signaling
|
S1P1 pathway
|
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
|
PDGFR-beta signaling pathway
|
Validated targets of C-MYC transcriptional repression
|
PDGF receptor signaling networkatf2_pathway:ATF-2 transcription factor network
|
PDGFR-alpha signaling pathway
|
PDGF receptor signaling networkglypican_1pathway:Glypican 1 network
|
HIF-2-alpha transcription factor network
|
VEGF and VEGFR signaling network
|
VEGFR1 specific signals
|
Signaling events mediated by VEGFR1 and VEGFR2hif2pathway:HIF-2-alpha transcription factor network
|
Integrins in angiogenesis
|
Signaling events mediated by VEGFR1 and VEGFR2
|
Notch-mediated HES/HEY network
|
Reactome
|
PIP3 activates AKT signaling
|
Constitutive Signaling by Aberrant PI3K in Cancer
|
RAF/MAP kinase cascadeR-HSA-1257604:PIP3 activates AKT signaling
|
RAF/MAP kinase cascadeR-HSA-194306:Neurophilin interactions with VEGF and VEGFR
|
VEGF binds to VEGFR leading to receptor dimerizationR-HSA-194306:Neurophilin interactions with VEGF and VEGFR
|
VEGF binds to VEGFR leading to receptor dimerization
|
Integrin cell surface interactions
|
EPHA-mediated growth cone collapse
|
VEGFA-VEGFR2 Pathway
|
VEGFR2 mediated cell proliferation
|
WikiPathways
|
Regulation of Actin Cytoskeleton
|
MAPK Signaling Pathway
|
Osteoblast Signaling
|
Focal Adhesion
|
PIP3 activates AKT signaling
|
PDGF Pathway
|
Signaling Pathways in Glioblastoma
|
Signaling by PDGFWP51:Regulation of Actin Cytoskeleton
|
Hair Follicle Development: Organogenesis (Part 2 of 3)
|
Cardiac Progenitor Differentiation
|
Integrated Pancreatic Cancer Pathway
|
Allograft Rejection
|
Signaling by PDGF
|
AngiogenesisWP306:Focal Adhesion
|
Signaling by VEGF
|
Nifedipine Activity
|
Angiogenesis
|
References |
REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6043). |
---|
REF 2 | J Med Chem. 2003 Mar 27;46(7):1116-9.Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. |